small molecule

RAVICTI

GLYCEROL PHENYLBUTYRATE

Loss of exclusivitySeptember 2030latest FDA-listed patent expiry
CompanyHORIZON THERAPEUTICS US HOLDING LLC

Drug detail

Brand nameRAVICTI
Active ingredientGLYCEROL PHENYLBUTYRATE
Strength1.1GM/ML
Dosage formLIQUID
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2013
Marketing statusRX

Listed patents

PatentExpiresType
9561197September 2030use U-1383
10183003September 2030use U-1816
10183002September 2030use U-1816
10183004September 2030use U-1816
8642012September 2030use U-1383
10045959September 2030use U-1816
9962359September 2030use U-1816
9326966September 2030use U-1816
10668040September 2030use U-1816
10183005September 2030use U-1816
10183006September 2030use U-1816
10045958September 2030use U-1816
9254278September 2030use U-1816
9999608September 2030use U-1816

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.